Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Cardiac Amyloidosis Market Growth in 2025?
In recent years, the market size of cardiac amyloidosis has experienced substantial growth. It is predicted to expand from $5.26 billion in 2024 to $5.75 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.2%. Factors contributing to this growth during the historical period include an increased incidence of conditions related to amyloidosis, a rise in genetic mutations, heightened awareness, a surge in cases of transthyretin amyloidosis, and a growing elderly population.
What Is the Forecast for the Cardiac Amyloidosis Market Size Through 2029?
Expectations are high for a robust growth in the cardiac amyloidosis market in the coming years. The market is projected to expand to $8.10 billion by the year 2029, with a compound annual growth rate (CAGR) of 9.0%. This predicted expansion within the forecast period is credited to factors like elevated diagnosis rates, government backing and strategies, a surge in genetic mutation occurrences, and patient assistance programs. The forecast period also indicates certain trends such as the innovation of therapies like vulrisiran, heightened research in the field of gene therapy, emphasis on precision medicine, enhancement in diagnostic technologies, and the discovery of novel therapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21128&type=smp
What are the Key Market Players in Cardiac Amyloidosis Market and How They’re Evolving?
Major companies operating in the cardiac amyloidosis market are Pfizer Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Alexion Pharmaceuticals Inc., Dr. Reddy’s Laboratories, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Amylyx Pharmaceuticals, Neurimmune AG, SOM Biotech, Oncopeptides, Attralus Inc., Eidos Therapeutics.
What Are the Primary Growth Drivers in the Cardiac Amyloidosis Market?
The growth of the cardiac amyloidosis market is anticipated to be driven by an escalating elderly population. The term geriatric population concerns people of 65 years or older, a demographic that often demands special medical care and assistance due to age-related deterioration. Factors such as enhanced life expectancy, healthcare progress, and reduced birth rates contribute to the growth of the elderly community. Consequently, the occurrence of cardiac amyloidosis escalates as older age significantly intensifies the risk of amyloid protein deposits in the heart. For example, the American-based non-profit, the Population Reference Bureau, projected in January 2024, the US population of 65 years or older would rise from 58 million in 2022 to 82 million by 2050, indicating a 47% growth. Thus, the expanding elderly population is likely to stimulate the cardiac amyloidosis market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21128&type=smp
What Are the Leading Segments in the Global Cardiac Amyloidosis Industry?
The cardiac amyloidosis market covered in this report is segmented –
1) By Product Type: Light Chain Amyloidosis, Transthyretin Amyloidosis
2) By Treatment: Chemotherapy, Surgery, Supportive Care, Stem Cell Transplant, Targeted Therapy
3) By End-User: Hospitals, Ambulatory Surgical Centres, Clinics
Subsegments:
1) By Light Chain Amyloidosis: Immunoglobulin Light Chain (AL) Amyloidosis, Primary Light Chain Amyloidosis, Secondary Light Chain Amyloidosis
2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm), Wild-type Transthyretin Amyloidosis (ATTRwt)
What Are the Key Market Trends in the Cardiac Amyloidosis Industry?
Leading corporations in the cardiac amyloidosis market are prioritizing technological advancements, such as software-only diagnostic tools that leverage artificial intelligence (AI), to boost initial detection and better patient clinical results associated with this often underdiagnosed illness. AI-based, software-only medical equipment enables cardiac amyloidosis detection by using AI to scrutinize echocardiographic images and recognize disease signs, void of necessitating any additional hardware or exhaustive clinical information. For example, Ultromics Ltd., a health technology firm based in the UK, obtained FDA approval in November 2024 for EchoGo Amyloidosis. This AI-enabled clinical device, designed for early cardiac amyloidosis detection, was the first to receive marketing approval under the FDA’s Total Product Lifecycle Advisory Program (TAP). EchoGo Amyloidosis uses AI to study echocardiograms and identify the disease from a single clip, addressing the pressing demand for earlier diagnosis before the disease advances undetected.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/cardiac-amyloidosis-global-market-report
What Is the Regional Outlook for the Cardiac Amyloidosis Market?
North America was the largest region in the cardiac amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21128
This Report Delivers Insight On:
1. How big is the cardiac amyloidosis market, and how is it changing globally?
2. Who are the major companies in the cardiac amyloidosis market, and how are they performing?
3. What are the key opportunities and risks in the cardiac amyloidosis market right now?
4. Which products or customer segments are growing the most in the cardiac amyloidosis market?
5. What factors are helping or slowing down the growth of the cardiac amyloidosis market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model